×
DURECT Total Liabilities 2010-2024 | DRRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DURECT total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
DURECT Total Liabilities 2010-2024 | DRRX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DURECT total liabilities from 2010 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.8B
Chugai Pharmaceutical (CHGCY)
$66.9B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$20.6B
Merck (MKKGY)
$20B
Astellas Pharma (ALPMY)
$17.7B
United Therapeutics (UTHR)
$16.6B
Summit Therapeutics (SMMT)
$16B
Neurocrine Biosciences (NBIX)
$15.3B
Shionogi (SGIOY)
$12.5B
Orion OYJ (ORINY)
$7.5B
Madrigal Pharmaceuticals (MDGL)
$7.1B
Stevanato Group S.p.A (STVN)
$6.5B
Corcept Therapeutics (CORT)
$6.4B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.2B
Ono Pharmaceutical (OPHLF)
$4.9B
Grifols, S.A (GRFS)
$4.8B
Crinetics Pharmaceuticals (CRNX)
$3.7B
Catalyst Pharmaceuticals (CPRX)
$2.9B
Recursion Pharmaceuticals (RXRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Centessa Pharmaceuticals (CNTA)
$2.2B
Soleno Therapeutics (SLNO)
$2.1B
Hypermarcas (HYPMY)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Indivior (INDV)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Evotec AG (EVO)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.4B